The patient’s disease progressed, and after more than two years and numerous treatments, patient #2’s cancer was dominated by a new subclone (SC5), derived from the ESR1-mutant subclone SC4, with CCF of ~100% (Fig. 2b). This evidence concerns the gene ESR1 and cancer.